scholarly journals Spontaneous tumour lysis syndrome at presentation in an infant with hepatoblastoma: A rare occurrence

2021 ◽  
Author(s):  
Srinivas Srinidhi Vadlapudi ◽  
Anshu Srivastava ◽  
Nilay Nishith ◽  
Moinak Sen Sarma ◽  
Ujjal Poddar ◽  
...  
Keyword(s):  
Tumour Lysis Syndrome ◽  
Rare Occurrence ◽  
Tumour Lysis

Spontaneous tumour lysis syndrome in multiple myeloma with loss of 17p13.1, t(4;14) and monosomy 13

2021 ◽  
Vol 14 (2) ◽  
pp. e234122
Author(s):  
Bushra Tbakhi ◽  
Sandrine Hanna ◽  
Yazan Samhouri ◽  
Deeraj Lingutla
Keyword(s):  
Multiple Myeloma ◽  
Rare Case ◽  
Medical Intervention ◽  
Tumour Cells ◽  
Tumour Lysis Syndrome ◽  
Rare Occurrence ◽  
Tumour Lysis ◽  
Oncological Emergency ◽  
Life Threatening ◽  
Threatening Situation

Tumour lysis syndrome (TLS) is a constellation of metabolic derangements caused by lysis of tumour cells. It is an oncological emergency that is considered a rare occurrence in multiple myeloma (MM) and usually occurs after patients have been treated with chemotherapy. We describe a very rare case of TLS occurring before the official diagnosis or treatment of MM. We report infrequent karyotype abnormalities, including loss of 17p13.1 (TP53 mutation), t(4;14) (FGFR3/IGH fusion) and monosomy 13, that have not been explicitly described in association with spontaneous tumour lysis syndrome (STLS) in MM. This case adds to the sparse literature available on STLS in MM, which is a life-threatening situation requiring urgent medical intervention.

scholarly journals P30-3 Clinical experience of tumour lysis syndrome in patients with extensive disease small cell lung cancer

2021 ◽  
Vol 32 ◽  
pp. S348
Author(s):  
Megumi Kawamoto ◽  
Yoshiyuki Sano ◽  
Yoshitaka Zenke ◽  
Kenji Kawasumi ◽  
Hiroki Izumi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Experience ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Tumour Lysis Syndrome ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
Tumour Lysis

Follow-Up Study on Management of Tumour Lysis Syndrome with Single Low Fixed Dose (1.5 mg) of Rasburicase - A Tertiary Cancer Centre Experience from India

2021 ◽  
Vol 8 (25) ◽  
pp. 2149-2154
Author(s):  
Alok Ranjan ◽  
Nisha Khanna ◽  
Vivek Ranjan ◽  
Ashwin Kumar
Keyword(s):  
Uric Acid ◽  
Single Dose ◽  
Tumour Lysis Syndrome ◽  
Urate Oxidase ◽  
Fixed Dose ◽  
Additional Dose ◽  
Tumour Lysis ◽  
Follow Up Study ◽  
Study Results

BACKGROUND Rasburicase (recombinant urate oxidase) has been proven to be an effective therapy for prevention of tumour lysis syndrome (TLS). The recommended daily dosing regimen of rasburicase is 0.2 mg/kg/day for 5 days which is expensive and unaffordable to many patients in the developing countries. The purpose of the present study was to evaluate the effect of single 1.5 mg dose rasburicase in the management of tumour lysis syndrome. METHODS This is a follow-up study done at our institute. Fifty (50) patients with tumour lysis syndrome who received rasburicase from August 2015 to January 2020 were enrolled in this study RESULTS Single dose of rasburicase is effective in decreasing serum uric acid level in significant number (N = 41) of patients. Percentage of patients having uric acid less than 7 mg after single dose of rasburicase in 48 hours - 82.9 % (N = 34) while 17 % (N = 7) were found to have uric acid levels of more than 7 mg/dl. The percentage of patients with uric acid levels more than 7 mg/dl reduced from 36.5 % after 24 hours to 17 % after 48 hours. This indicates that the uric acid levels show a declining trend even after 24 hours without giving an additional dose of rasburicase. There was no relationship between uric acid levels at 24 hours and percentage change in creatinine level from baseline to 24 hours (correlation coefficient (r) = -0.047, P = 0.770. Patients who required additional dose (N = 9) had high base line value of uric acid and their high value was maintained over the follow up period of three days. Patients with pre exiting kidney disease and high level of baseline uric acid also needed dialysis (N = 3). CONCLUSIONS In majority of patients, a single 1.5 mg dose of rasburicase is an effective way to reduce raised uric acid in appropriate circumstances. KEYWORDS Single Dose, Recombinant Urate Oxidase, Uric Acid, Leukemia, Tumour Lysis Syndrome, Rasburicase

scholarly journals Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer

2013 ◽  
Vol 2013 (apr23 1) ◽  
pp. bcr2013009532-bcr2013009532 ◽  
Author(s):  
M. Camarata ◽  
R. Davies ◽  
S. Copley ◽  
S. Blagden
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Tumour Lysis Syndrome ◽  
Tumour Lysis

scholarly journals Metastatic choriocarcinoma with tumour lysis syndrome

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Birthe Osorio ◽  
Heidrun Männle ◽  
Karsten Münstedt
Keyword(s):  
Tumour Lysis Syndrome ◽  
Tumour Lysis

scholarly journals Evolving concepts in tumour lysis syndrome management

2015 ◽  
Vol 173 (3) ◽  
pp. 485-486 ◽  
Author(s):  
Soufia Ayed ◽  
Caroline Bornstain ◽  
François Vincent
Keyword(s):  
Tumour Lysis Syndrome ◽  
Tumour Lysis
Sign in / Sign up

Export Citation Format

Share Document